Stock SBLOF SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Shin Nippon Biomedical Laboratories, Ltd. OTC Markets

Equities

SBLOF

JP3379950003

Market Closed - OTC Markets
Other stock markets
 16:58:04 16/05/2023 BST 		5-day change 1st Jan Change
16.97 USD -.--% Intraday chart for Shin Nippon Biomedical Laboratories, Ltd. -.--% -.--%
05-08 Shin Nippon Biomedical Laboratories, Ltd. Announces Fiscal Year End Dividend for the Fiscal Year Ended March 31, 2024, Payable on June 25, 2024; Provides Second Quarter End and Fiscal Year End Dividend Guidance for the Fiscal Year Ended March 31, 2025 CI
05-08 Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Forecasts for the Six Months Ending September 30, 2024 and Year Ending March 31, 2025 CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Shin Nippon Biomedical Laboratories, Ltd. Announces Fiscal Year End Dividend for the Fiscal Year Ended March 31, 2024, Payable on June 25, 2024; Provides Second Quarter End and Fiscal Year End Dividend Guidance for the Fiscal Year Ended March 31, 2025
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Forecasts for the Six Months Ending September 30, 2024 and Year Ending March 31, 2025
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024
Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending March 31, 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending March 31, 2024
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024
Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific Meeting
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers.
Shin Nippon Biomedical Laboratories, Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024
Shin Nippon Biomedical Laboratories, Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024
Sector Update: Health Care Stocks Higher Premarket Monday
Bank Earnings in Focus as US Equity Futures Tread Water
Top Premarket Gainers
Satsuma Pharmaceuticals to be Acquired by Shin Nippon Biomedical
Shin Nippon Biomedical Laboratories, Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023
Shin Nippon Biomedical Laboratories, Ltd. Revises Year End Dividend Guidance for the Year Ending March 31, 2023
Shin Nippon Biomedical Laboratories, Ltd. Announced Dividend for the Second Quarter of Fiscal Year Ending March 31, 2023, Commence Payments from November 30, 2022
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2395 Stock
  4. SBLOF Stock
  5. News Shin Nippon Biomedical Laboratories, Ltd.
  6. Other languages